Syndax Pharmaceuticals at Citigroup’s Biopharma Back to School Summit 2026: revuforj gains
Syndax Pharmaceuticals (SNDX) reported strong growth for its lead drug, Revuforj, with $55 million in quarterly revenue and 85% market share in relapse-refractory AML. The company is advancing pivotal studies to expand Revuforj's use and developing a pipeline in lung cancer and myelofibrosis. Management highlighted Revuforj's potential peak revenue of over $2 billion, pending clinical and commercial success.
How this was made
The 30-second read
Why it matters
The update confirms existing growth trends but adds no new data; traders may hold positions pending upcoming trial readouts.
Market read
Limited immediate trading impact; focus remains on future clinical data releases.
What to watch
Upcoming readouts in Q4 2024 for IPF trial could materially shift valuation if results are negative.
Background
Syndax presented its latest commercial performance and pipeline milestones at a Citi biotech conference.
Ticker impact
Management highlighted Revuforj revenue growth and pipeline updates at the Citigroup Biopharma Summit, providing fresh commentary on sales and trial progress.
Modest upside potential if quarterly results confirm guidance; downside if trial timelines slip.
Revenue figures are disclosed, but no new trial data; market reaction likely limited to reaffirmation of existing expectations.
Market effects
Reinforces positive outlook for the menin inhibitor niche within hematology/oncology.
US biotech sentiment modestly supported; limited impact on broader markets.
Low; primarily relevant to investors tracking Syndax and similar biotech peers.
Counterpoint
Execution risk in expanding Revuforj earlier in treatment could delay revenue growth.
Key entities
- companySyndax Pharmaceuticals
Biotech firm developing Revuforj and other pipeline assets.
